BAP1 and nonpapillary renal cell carcinoma: However, BAP1 mutation was observed in 25% of patients, which is slightly higher than the value obtained in other studies, perhaps because our cohort comprised patients with more aggressive ccRCC; we intentionally collected aggressive ccRCC to pair with non-aggressive ccRCC.